Please check your internet connection and try again.
# IV Hydrocortisone for Acute Asthma
## Overview
Intravenous (IV) hydrocortisone is a corticosteroid used as adjunctive therapy in moderate to severe acute asthma exacerbations when patients do not respond adequately to initial bronchodilator therapy. It works by reducing airway inflammation.
## Primary Indications
Adjunctive treatment for moderate to severe acute asthma exacerbations in patients requiring hospitalization or not responding to initial bronchodilator therapy.
## Adult Dosing
* **Dose:** Typically 100 mg IV every 6-8 hours.
* **Maximum:** Not explicitly defined, but doses are generally within this range.
* **Duration:** Treatment duration is guided by clinical response and may last for 24-72 hours. Transition to oral steroids as soon as clinically feasible.
## Pediatric Dosing
* **Dose:** 2-4 mg/kg IV every 6-8 hours.
* **Maximum:** 100 mg per dose.
* **Duration:** Similar to adults, guided by clinical response and transition to oral steroids when appropriate.
## Dose Adjustments
* **Renal Impairment:** No specific dose adjustment is routinely recommended. Monitor for potential increased adverse effects.
* **Hepatic Impairment:** No specific dose adjustment is routinely recommended. Monitor for potential increased adverse effects.
## Contraindications
* Known hypersensitivity to hydrocortisone or any component of the formulation.
* Systemic fungal infections.
## Adverse Effects
Common adverse effects include hyperglycemia, insomnia, mood changes, increased appetite, and fluid retention. Less common but serious effects include adrenal suppression, increased susceptibility to infection, peptic ulceration, growth suppression (in children with prolonged use), and myopathy.
## Key Drug Interactions
* **CYP3A4 Inducers (e.g., rifampin, phenytoin, phenobarbital):** May decrease hydrocortisone levels and efficacy.
* **CYP3A4 Inhibitors (e.g., ketoconazole, macrolides):** May increase hydrocortisone levels.
* **Potassium-depleting agents (e.g., diuretics, amphotericin B):** Increased risk of hypokalemia.
* **Vaccines (live virus):** Avoid during treatment due to increased risk of infection.
## Monitoring
* **Clinical response:** Assess respiratory rate, oxygen saturation, work of breathing, and peak expiratory flow rates.
* **Electrolytes:** Particularly potassium and glucose, especially in patients with risk factors or prolonged use.
* **Signs of infection:** Monitor for fever, elevated white blood cell count, or other signs of new infection.
* **Adrenal function:** Consider assessment of HPA axis suppression after prolonged or high-dose therapy.
## Clinical Pearls
* IV hydrocortisone provides a slower onset of action compared to inhaled bronchodilators and is considered adjunctive therapy.
* Early administration may be beneficial, but consensus on the optimal timing is lacking.
* The effectiveness of IV hydrocortisone in acute asthma is debated, and many guidelines now emphasize early and adequate use of oral corticosteroids in mild to moderate exacerbations.
* Transition to oral prednisone or prednisolone as soon as the patient can tolerate oral intake and demonstrates clinical improvement.
* Stress dosing (higher doses) is not typically indicated for acute asthma exacerbations.
***
*This information is intended for healthcare professionals. Always consult the most current prescribing information and local protocols for definitive guidance. This information does not replace independent clinical judgment.*
